|
|
|
|
|
Detail |
hsa-miR-101 |
|
Unspecified |
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. |
2004 |
|
|
|
|
|
|
hsa-miR-101 |
|
Unspecified |
Distinctive patterns of microRNA expression in primary muscular disorders. |
2007 |
|
|
|
|
|
|
hsa-miR-101 |
|
Unspecified |
MicroRNA signatures in human ovarian cancer. |
2007 |
|
|
|
|
|
|
hsa-miR-101 |
|
Unspecified |
High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. |
2007 |
|
|
|
|
|
|
hsa-miR-101 |
|
Unspecified |
Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. |
2008 |
|
|
|
|
|
|
hsa-miR-101 |
|
Unspecified |
Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. |
2009 |
|
|
|
|
|
|
hsa-miR-101 |
|
Unspecified |
MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. |
2009 |
|
|
|
|
|
|
hsa-miR-101 |
|
Unspecified |
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. |
2008 |
|
|
|
|
|
|
hsa-miR-101 |
|
Causal |
MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma. |
2009 |
|
|
|
|
|
|
hsa-miR-101 |
|
Causal |
miR-19, miR-101 and miR-130 co-regulate ATXN1 levels to potentially modulate SCA1 pathogenesis. |
2008 |
|
|
|
|
|
|
hsa-miR-101 |
|
Causal |
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. |
2009 |
|
|
|
|
|
|
hsa-miR-101 |
|
Causal |
MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. |
2009 |
|
|
|
|
|
|
hsa-miR-101 |
|
Causal |
The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. |
2009 |
|
|
|
|
|
|
hsa-miR-101 |
|
Causal |
Commentary on Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer |
2009 |
|
|
|
|
|
|